|
May 2
|
ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians
|
|
May 2
|
ALK enters into neffy® co-promotion agreement in the USA
|
|
Apr 29
|
Invitation to the presentation of ALK’s first quarter 2025 results on Tuesday, 6 May 2025
|
|
Jan 22
|
3 Stocks Estimated To Be Trading At Discounts Of 26% To 44%
|